Literature DB >> 2193099

Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients.

A P Limaye1, J S Abrams, J E Silver, E A Ottesen, T B Nutman.   

Abstract

Production of the eosinophilogenic cytokines interleukin 3 (IL-3), granulocyte/macrophage colony-stimulating factor (GM-CSF), and IL-5 by mitogen-stimulated peripheral blood mononuclear cells was compared between 11 noneosinophilic individuals and seven patients with helminth-induced eosinophilia. Both the kinetics and quantities of IL-3 and GM-CSF were similar in the two groups. In contrast, IL-5 production at both the protein and the mRNA level was markedly greater in the eosinophilic patients, an observation suggesting that IL-5 may be particularly important in mediating the selective eosinophilia seen in filarial and other helminth infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193099      PMCID: PMC2188151          DOI: 10.1084/jem.172.1.399

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

1.  Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni.

Authors:  A Sher; R L Coffman; S Hieny; P Scott; A W Cheever
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice.

Authors:  R L Coffman; B W Seymour; S Hudak; J Jackson; D Rennick
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

4.  T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation.

Authors:  H Enokihara; S Furusawa; H Nakakubo; H Kajitani; S Nagashima; K Saito; H Shishido; Y Hitoshi; K Takatsu; T Noma
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

5.  T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome.

Authors:  A Raghavachar; S Fleischer; N Frickhofen; H Heimpel; B Fleischer
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

6.  Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4.

Authors:  R Bacchetta; R de Waal Malefijt; H Yssel; J Abrams; J E de Vries; H Spits; M G Roncarolo
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

7.  Mechanism of eosinophilia. II. Role of the lymphocyte.

Authors:  A Basten; P B Beeson
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

8.  Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome.

Authors:  W F Owen; M E Rothenberg; J Petersen; P F Weller; D Silberstein; A L Sheffer; R L Stevens; R J Soberman; K F Austen
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

9.  Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.

Authors:  A F Lopez; L B To; Y C Yang; J R Gamble; M F Shannon; G F Burns; P G Dyson; C A Juttner; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

10.  Mechanism of eosinophilia. I. Factors affecting the eosinophil response of rats to Trichinella spiralis.

Authors:  A Basten; M H Boyer; P B Beeson
Journal:  J Exp Med       Date:  1970-06-01       Impact factor: 14.307

View more
  34 in total

1.  Eosinophils in health and disease: the LIAR hypothesis.

Authors:  J J Lee; E A Jacobsen; M P McGarry; R P Schleimer; N A Lee
Journal:  Clin Exp Allergy       Date:  2010-04       Impact factor: 5.018

2.  The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice.

Authors:  M Korenaga; Y Hitoshi; N Yamaguchi; Y Sato; K Takatsu; I Tada
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

3.  Relevance of ex vivo blood lymphocyte assay for in vivo lymphocyte function.

Authors:  N W Brattig; C Timmann; R S Abraha; B Lepping; B Müller-Myhsok; R D Horstmann
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

Review 4.  Transgenic mice in the study of cytokine function.

Authors:  J Taverne
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

5.  An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness.

Authors:  L R Hall; R K Mehlotra; A W Higgins; M A Haxhiu; E Pearlman
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Mechanisms of eosinophilia in BALB/c-nu/+ and congenitally athymic BALB/c-nu/nu mice infected with Toxocara canis.

Authors:  Y Kusama; M Takamoto; T Kasahara; K Takatsu; H Nariuchi; K Sugane
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

7.  Mechanisms of eosinophilia in mice infested with larval Haemaphysalis longicornis ticks.

Authors:  H Ushio; S Hirota; T Jippo; S Higuchi; K Kawamoto; Y Kitamura; H Matsuda
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

8.  Mapping of the interleukin 5 receptor gene to human chromosome 3 p25-p26 and to mouse chromosome 6 close to the Raf-1 locus with polymorphic tandem repeat sequences.

Authors:  C O Jacob; K Mykytyn; T Varcony; H A Drabkin
Journal:  Mamm Genome       Date:  1993       Impact factor: 2.957

9.  IL-5 in post-traumatic eosinophilic pleural effusion.

Authors:  L Schandené; B Namias; A Crusiaux; M Lybin; R Devos; T Velu; P Capel; R Bellens; M Goldman
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

10.  Modulation of cellular and humoral immunity, and disease manifestation during onset of patency in Brugia pahangi-infected dogs.

Authors:  D Schreuer; B Hammerberg
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.